UBS Group’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

UBS Group’s Portfolio OSIR Stock Details OSIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-7,699	Closed	-$146K	–	8553
2019 Q1	$146K	Buy	7,699 +1,482	+24%	+$24K	﹤0.01%	4814
2018 Q4	$84K	Hold	6,217	–	–	﹤0.01%	5692
2018 Q3	$69K	Buy	+6,217	New	+$62.2K	﹤0.01%	5909
2017 Q1	–	Sell	-5,694	Closed	-$28K	–	8444
2016 Q4	$28K	Buy	5,694 +1,944	+52%	+$9.96K	﹤0.01%	6304
2016 Q3	$19K	Sell	3,750 -743	-17%	-$3.8K	﹤0.01%	6366
2016 Q2	$23K	Sell	4,493 -91	-2%	-$490	﹤0.01%	6202
2016 Q1	$27K	Sell	4,584 -121	-3%	-$845	﹤0.01%	5995
2015 Q4	$49K	Buy	4,705 +1,569	+50%	+$21.3K	﹤0.01%	5847
2015 Q3	$58K	Buy	3,136 +436	+16%	+$8.41K	﹤0.01%	5709
2015 Q2	$53K	Sell	2,700 -4,959	-65%	-$87.8K	﹤0.01%	5977
2015 Q1	$134K	Buy	7,659 +3,659	+91%	+$61.5K	﹤0.01%	5197
2014 Q4	$64K	Buy	+4,000	New	+$53.6K	﹤0.01%	6197

Other funds holding OSIR

FGAM

Financial Gravity Asset Management Lakeway, Texas $562M AUM

UBS Group's OSIR Position: Q2 2019 in Review

UBS Group sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q2 2019, closing a stake of 7,699 shares — an estimated $146K sold.

UBS Group first reported a position in OSIR in Q4 2014 and held it in 12 quarters. The position peaked at $146K in Q1 2019. 1 fund tracked by Wall St. Rank holds OSIR as of Q2 2019.

UBS Group reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
UBS Group sold 7,699 Osiris Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $146K.
UBS Group first reported a position in Osiris Therapeutics, Inc. Common Stock in Q4 2014 and held it in 12 quarters.
UBS Group's Osiris Therapeutics, Inc. Common Stock position peaked at $146K in Q1 2019.
1 fund tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q2 2019.

Based on UBS Group's 13F filing for Q2 2019, filed 14 Aug 2019.